Li Tan
13Patents
5h-index
12Co-inventors
55Inventor score
Filing activity: Jul 9, 2014 → Nov 24, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9783504B2 | Kinase inhibitors for the treatment of disease | Emerging Cross-Sectional Technologies | 20 | Active |
| US9862688B2 | Hydrophobically tagged janus kinase inhibitors and uses thereof | Chemistry; Metallurgy | 20 | Active |
| US10017477B2 | Janus kinase inhibitors and uses thereof | Chemistry; Metallurgy | 17 | Active |
| US10316002B2 | Kinase inhibitors for the treatment of disease | Emerging Cross-Sectional Technologies | 8 | Active |
| US9856223B2 | Methods to treat lymphoplasmacytic lymphoma | Chemistry; Metallurgy | 6 | Active |
| US9908872B2 | Methods to treat lymphoplasmacytic lymphoma | Chemistry; Metallurgy | 5 | Active |
| US10525060B2 | HCK as a therapeutic target in MYD88 mutated diseases | Human Necessities | 3 | Active |
| US10633348B2 | Methods to treat lymphoplasmacytic lymphoma | Chemistry; Metallurgy | 1 | Active |
| US10597387B2 | Methods to treat lymphoplasmacytic lymphoma | Chemistry; Metallurgy | 1 | Active |
| US10124008B2 | Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations | Human Necessities | 1 | Active |
| USRE50030E1 | Methods to treat lymphoplasmacytic lymphoma | General | 0 | Active |
| US10925868B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | Chemistry; Metallurgy | 0 | Active |
| US10906878B2 | Kinase inhibitors for the treatment of disease | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.